Trabikibart Biosimilar Monoclonal Antibody (CD131) for Research

Cat No.: GMP-Bios-INN-1425

Anti-CSF2RB/CD131/IL3RB/IL5RB therapeutic antibody (Pre-made Trabikibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Trabikibart (development code CSL311) is a monoclonal antibody targeting CSF2RB. It is developed by CSL for Asthma in Phase I development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1425-1mg 1mg 3090
GMP-Bios-INN-1425-10mg 10mg
GMP-Bios-INN-1425-100mg 100mg
GMP-Bios-INN-1425-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Trabikibart biosimilar, Whole mAb, Anti-CSF2RB/CD131/IL3RB/IL5RB Antibody: Anti-IL-3RB/CD131/CSF2RB/Cytokine receptor common subunit beta therapeutic antibody
INN Name Trabikibart
Target CSF2RB/CD131/IL3RB/IL5RB
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G4
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Active
100% SI Structure 5dwu:HL
99% SI Structure None
95-98% SI Structure None
Year Proposed 2023
Year Recommended 2023
Companies CSL
Conditions Approved na
Conditions Active Asthma
Conditions Discontinued na
Production na
Development Tech na